^McCormick F, Fabbro D (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. doi:10.1385/1-59259-962-1:001. ISBN1-58829-384-X.
^Mitscher LA, Lednicer D (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN0-470-10750-2.
^Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN978-0-470-19039-5.
^Clinical trial number NCT00034281 for "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2" at ClinicalTrials.gov
August 25, 2023
mubritinib, protein, kinase, inhibitor, which, under, development, takeda, treatment, cancer, completed, phase, clinical, trials, appears, have, been, discontinued, information, drug, surfaced, since, december, 2008, clinical, dataroutes, ofadministrationorala. Mubritinib TAK 165 is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer 1 2 3 It completed phase I clinical trials but appears to have been discontinued as no new information on the drug has surfaced since December 2008 4 MubritinibClinical dataRoutes ofadministrationOralATC codenoneLegal statusLegal statusIn general uncontrolledIdentifiersIUPAC name 1 4 4 2 E 2 4 trifluoromethyl phenyl ethenyl 1 3 oxazol 4 yl methoxy phenyl butyl 1H 1 2 3 triazoleCAS Number366017 09 6PubChem CID6444692IUPHAR BPS6011ChemSpider4948554UNIIV734AZP9BRChEMBLChEMBL1614707Chemical and physical dataFormulaC 25H 23F 3N 4O 2Molar mass468 480 g mol 13D model JSmol Interactive imageSMILES FC F F c1ccc cc1 C C c2nc co2 COc3ccc cc3 CCCCn4nncc4InChI InChI 1S C25H23F3N4O2 c26 25 27 28 21 9 4 20 5 10 21 8 13 24 30 22 18 34 24 17 33 23 11 6 19 7 12 23 3 1 2 15 32 16 14 29 31 32 h4 14 16 18H 1 3 15 17H2 b13 8 Key ZTFBIUXIQYRUNT MDWZMJQESA NSee also EditProtein kinase inhibitorReferences Edit McCormick F Fabbro D 2005 Protein Tyrosine Kinases From Inhibitors to Useful Drugs Cancer Drug Discovery and Development Totowa NJ Humana Press doi 10 1385 1 59259 962 1 001 ISBN 1 58829 384 X Mitscher LA Lednicer D 1977 The organic chemistry of drug synthesis New York Wiley ISBN 0 470 10750 2 Lednicer D 2008 Strategies for Organic Drug Synthesis and Design New York Wiley Interscience ISBN 978 0 470 19039 5 Clinical trial number NCT00034281 for Safety and Tolerability Study of TAK 165 in Subjects With Tumors Expressing HER2 at ClinicalTrials gov Retrieved from https en wikipedia org w index php title Mubritinib amp oldid 1147749861, wikipedia, wiki, book, books, library,
